MTP7 Antibody

What is MTP7 Antibody and what variants are available for research?

MTP7 refers to multiple entities in scientific literature, primarily Matrix Metalloproteinase-7 (MMP-7) antibodies and Metal Tolerance Protein 7 (in plants). For research purposes, several antibody types are available:

• GSM-192: A highly selective monoclonal antibody that specifically inhibits MMP-7 enzyme activity with high affinity (IC₅₀ = 132 ± 10 nM)

• Polyclonal antibodies: Available in unconjugated forms for applications including Western blotting, immunohistochemistry and immunocytochemistry

• Plant-specific MTP7 antibodies: Rabbit polyclonal antibodies against Oryza sativa subsp. japonica (Rice) MTP7 protein

The choice depends on your research focus, with GSM-192 being preferred for functional inhibition studies, while polyclonal antibodies are suitable for detection applications.

How does the structure of anti-MMP-7 monoclonal antibody GSM-192 relate to its function?

The structure-function relationship of GSM-192 has been well-characterized through computational modeling and docking:

• The atomic model of the MMP-7-GSM-192 Fab complex shows antibody binding to unique epitopes at the rim of the enzyme active site

• This binding sterically prevents substrate entry into the catalytic cleft

• Normal modes analysis applied to experimental structures showed mobility of the loops affecting the width of the active site cleft

• The structural configuration enables GSM-192 to specifically target the catalytically active conformation of MMP-7 rather than the zymogen form

This specific mechanism of action makes GSM-192 valuable for selectively inhibiting MMP-7's enzymatic activity without affecting other matrix metalloproteases.

What is the recommended protocol for generating function-blocking monoclonal antibodies against MMP-7?

Based on successful development of GSM-192, the following sequential immunization strategy is recommended:

• Initial immunization: Immunize female BALB/c mice with complete Freund's adjuvant and 30 μg of either:

  • Catalytic domain of MMP-7

  • Zn Tripod-KLH (active site mimicry antigen)

• Boosting regimen: Boost every 2 weeks with incomplete Freund's adjuvant via subcutaneous injection, alternating between the catalytic domain and active site mimicry antigens

• Screening: Test mouse bleeds for reactivity to antigens via ELISA

• Hybridoma generation:

  • Collect spleens from selected mice and fuse B cells with NSO murine myeloma cells

  • Screen hybridomas via ELISA

  • Subclone and expand selected hybridomas in tissue culture

• Antibody production: Grow hybridoma cells in serum-free medium designed for hybridoma cell growth (e.g., DCCM)

This alternating immunization approach with both active site mimicry antigen and activated enzyme has proven superior for generating inhibitory antibodies against the active conformation of MMP-7.

What are the most effective methods for purifying anti-MMP-7 antibodies?

The purification process should be tailored to the antibody type and intended application:

For monoclonal antibodies (e.g., GSM-192):

• Grow hybridoma cells in serum-free medium

• Precipitate cells by centrifugation (193× g)

• Purify using protein G affinity chromatography

For polyclonal antibodies:

• Perform antigen-specific affinity chromatography

• Follow with Protein A affinity chromatography

• Buffer in 0.01M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol

The purification method significantly impacts antibody performance and should be selected based on the required purity level and intended application.

How can MMP-7 antibodies be used to study cancer progression mechanisms?

MMP-7 antibodies, particularly GSM-192, serve as valuable tools for investigating several cancer progression mechanisms:

• Apoptosis regulation: Treatment with GSM-192 induces apoptosis via stabilization of cell surface Fas ligand, allowing researchers to study MMP-7's role in preventing apoptosis

• Cell migration studies: GSM-192 retards cell migration, enabling investigation of MMP-7's role in enhancing tumor invasiveness

• Chemoresistance mechanisms:

  • MMP-7 processing of the Fas/FasL system is implicated in drug resistance

  • Co-treatment with GSM-192 and chemotherapeutics (gemcitabine and oxaliplatin) elicits synergistic effects, providing a model to study resistance mechanisms

• Signaling pathway analysis:

  • Study MMP-7's role in IL-17 mediated epithelial-to-mesenchymal transition

  • Investigate MMP-7 as a pro-invasive effector molecule via the Wnt/β-catenin pathway

• Tumor microenvironment: Examine MMP-7's effects on both tumor cells and stromal cells

These applications make MMP-7 antibodies essential for understanding the multifaceted roles of MMP-7 in tumorigenesis and for validating it as a drug target.

What are the optimal working dilutions for different experimental applications of anti-MMP-7 antibodies?

The optimal working dilutions vary by application and specific antibody preparation:

It's essential to note that optimal working dilutions must be determined empirically by each laboratory, as they depend on:

• Specific antibody batch characteristics

• Sample type and preparation

• Detection method

• Target protein expression levels

Titration experiments are strongly recommended when using these antibodies in new experimental systems.

How can computational modeling enhance the development and characterization of MMP-7 antibodies?

Computational modeling provides crucial insights for antibody development and characterization:

• Structure-based epitope analysis:

  • Analysis of MMP-7 structures from PDB reveals variations affecting the width of the active site cleft

  • Normal modes analysis applied to experimental structures shows similar mobility of loops

• Docking simulations:

  • Computational docking of Fv domains to MMP-7 predicts binding interfaces

  • Multiple conformers of MMP-7 should be used in docking to account for structural flexibility

• Humanization design:

  • Sequence and structural criteria guide selection of human germlines for antibody humanization

  • Selection criteria include: similarity to mouse germlines, sequence identity with similar canonical structures, and compatibility between V-domains

• Stability prediction:

  • Computational tools can identify potentially destabilizing residues in antibody frameworks

  • Models can predict how humanization might affect binding affinity and stability

These computational approaches accelerate antibody development by reducing the number of variants that need to be experimentally tested, while increasing the likelihood of success.

What methods can be used for full validation of therapeutic anti-MMP-7 antibody sequences?

Complete validation of therapeutic antibody sequences requires multiple complementary approaches:

• Middle-up mass spectrometry analysis:

  • Fragment antibody using IdeS enzyme (from S. pyogenes) in the hinge region into Fc/2 and Fd domains

  • Perform reductive separation of the light chain

  • Analyze using MALDI-ISD (Matrix-Assisted Laser Desorption/Ionization-In-Source Decay)

• De novo protein sequencing:

  • TD (Top-Down) and MD (Middle-Down) protein sequencing using MALDI-ISD

  • Target 70% sequence coverage as a minimum standard

• High-resolution mass determination:

  • Perform intact high-resolution and high mass accuracy molecular weight determination of antibody LC, Fc/2, and Fd domains

  • Use Ultra High Resolution (UHR) QTOF mass spectrometry for isotopically resolved MW determination

• Sequence Validation Percentage (SVP):

  • Apply this quantitative measure to assess result validity and integrity

  • Account for gaps in sequence readout due to limitations of MDS analysis

• Western blotting for cross-reactivity:

  • Examine antibody cross-reactive material (CRM) in relevant samples

  • Identify potential second forms of CRM with different molecular weights

This comprehensive validation approach ensures the integrity and specificity of therapeutic antibodies intended for clinical development.

How can I optimize antibody titration for flow cytometry experiments?

Optimizing antibody titration for flow cytometry can be streamlined through automation:

• Automated methodology:

  • Utilize automated liquid handlers (e.g., Biomek i7 Multichannel workstation) integrated with flow cytometers (e.g., CytoFLEX LX)

  • This minimizes user interactions, reduces human error, and increases walk-away time

• Concentration series setup:

  • Prepare serial dilutions of antibody

  • Use consistent cell numbers across all samples (typically 1×10⁶ cells per test)

  • Include unstained and isotype controls

• Stain Index calculation:

  • Use integrated software platforms (e.g., Cytobank) that can perform both data analysis and Stain Index (SI) calculations

  • SI = (MFI positive - MFI negative) / (2 × SD of MFI negative)

• Determining optimal concentration:

  • Plot Stain Index against antibody concentration

  • Identify the plateau region of the curve

  • Select the lowest concentration that achieves maximum or near-maximum Stain Index

This approach prevents common issues like incomplete labeling (too little antibody) or increased background and non-specific binding (too much antibody), ensuring reliable and reproducible results.

What are the common challenges in generating conformation-specific antibodies against MMP-7, and how can they be addressed?

Generating conformation-specific antibodies against MMP-7 presents several challenges:

The successful generation of GSM-192 demonstrates that these challenges can be overcome through careful immunization strategy design, innovative antigen preparation, and rigorous screening protocols. This approach yields antibodies capable of specifically inhibiting the activated form of MMP-7 while discriminating against other MMP family members.

How might long-acting anti-MTP antibodies inform future therapeutic approaches?

Recent research with anti-Matriptase-2 (MTP-2) antibodies provides insights for developing long-acting therapeutic antibodies:

• Extended half-life engineering:

  • Anti-MTP-2 antibody demonstrates remarkable half-life (204 hours at 1 mg/kg; 348 hours at 3 mg/kg)

  • This extended half-life enables sustained pharmacological effects over 4 weeks from a single dose

• Dose-dependent pharmacokinetics:

  • C_max and AUC increase proportionally with dosage

  • This predictable relationship facilitates precise dosing regimens

• Humanized FcRn models:

  • Using Tg32 mouse models with humanized FcRn provides translatable PK/PD data

  • This approach better predicts human pharmacokinetics than standard mouse models

• Rapid onset combined with sustained action:

  • Effects reached approximately 70% reduction from baseline within 24 hours

  • Effects remained at low levels throughout the study period (4 weeks)

These principles could inform the development of long-acting anti-MMP-7 antibodies that combine rapid onset with sustained inhibition, potentially improving patient compliance and therapeutic outcomes in cancer treatment.

What novel applications might emerge from combining MMP-7 antibodies with other therapeutic modalities?

Several innovative therapeutic approaches could emerge from combining MMP-7 antibodies with other modalities:

• Antibody-drug conjugates (ADCs):

  • Leverage GSM-192's specificity to deliver cytotoxic payloads to MMP-7-expressing tumor cells

  • This could enhance therapeutic index while reducing systemic toxicity

• Bispecific antibodies:

  • Develop bispecific formats targeting both MMP-7 and immune checkpoints

  • This approach could combine inhibition of tumor invasion with enhanced T-cell activity

• Combination with chemotherapeutics:

  • Build on observed synergy between GSM-192 and conventional chemotherapeutics (gemcitabine and oxaliplatin)

  • Develop optimized dosing regimens to maximize this synergistic effect

• Immunomodulatory combinations:

  • Given MMP-7's role in Fas/FasL processing and apoptosis evasion

  • Combine with immunotherapies that promote tumor-specific T-cell activity

• Diagnostic-therapeutic combinations:

  • Develop imaging agents based on GSM-192 to identify patients likely to respond to MMP-7-targeting therapies

  • This could enable personalized treatment approaches

These combinatorial approaches could address the multifaceted roles of MMP-7 in cancer and inflammation, potentially overcoming resistance mechanisms and improving clinical outcomes.